전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved63 programs
AntibodyLimited DatastaleMedical College of WisconsinPhase 1

atezolizumab (Tecentriq, Adjuvant Atezolizumab)

Head and Neck Neoplasm · Head and Neck Neoplasm

#HeadandNeckNeoplasm#Antibody#Phase1#monoclonal-antibody#Medical
Trials 1Status Active
AntibodyLimited DatastaleKymab LimitedPhase 2

Alomfilimab (Alomfilimab)

Squamous Cell Carcinoma of Head and Neck; Non-small Cell Lung Cancer · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleBayerPhase 1

BAY1905254 (Bapotulimab, Bapotulimab (BAY1905254))

Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleMerckPhase 1

pembrolizumab (Keytruda, BAY1905254, Bapotulimab, Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®))

Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
ADCLimited DatastaleWest China HospitalPhase 2

Becotatug Vedotin Combined with Ivonescimab (Becotatug Vedotin Combined with Ivonescimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#antibody-drug-conjugate#West
Trials 1Status Recruiting
ADCLimited DatastaleFeng LiuPhase 2

Becotatug Vedotin Combined with PD-1 Inhibitor (Becotatug Vedotin Combined with PD-1 Inhibitor)

Head and Neck Squamous Cell Carcinoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleWest China HospitalPhase 2

Becotatug Vedotin Combined with Penpulimab (Becotatug Vedotin Combined with Penpulimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#antibody-drug-conjugate#West
Trials 1Status Recruiting
ADCLimited DatastaleShanghai Ninth People's Hospita…Phase 2

Becotatug Vedotin combined with Pucotenlimab (Becotatug Vedotin combined with Pucotenlimab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#ADC#Phase2#antibody-drug-conjugate#Shanghai
Trials 1Status Recruiting
ADCLimited DatastaleShanghai Ninth People's Hospita…Phase 2

sacituzumab govitecan (Trodelvy, Becotatug Vedotin or Sacituzumab Tirumotecan)

Adenoid Cystic Carcinoma of the Head and Neck; SBRT · Adenoid Cystic Carcinoma of the Head and

#AdenoidCysticCarcinomaoftheHeada#ADC#Phase2#antibody-drug-conjugate#SBRT+1
Trials 1Status Recruiting
AntibodyLimited DatastaleTaizhou Mabtech Pharmaceutical …Phase 1

CMAB819 (CMAB819)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase1#monoclonal-antibody#Taizhou
Trials 1Status Discontinued
AntibodyLimited DatastaleJiangsu HengruiPhase 3

Camrelizumab and Cetuximab (Camrelizumab and Cetuximab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Jiangsu
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 3

Camrelizumab and Chemotherapy (Camrelizumab and Chemotherapy)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Jiangsu
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab+cetuximab+chemotherapy (Camrelizumab+cetuximab+chemotherapy)

Squamous Cell Carcinoma of Head and Neck · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Active
AntibodyLimited DatastaleMedical College of WisconsinPhase 1

atezolizumab (Tecentriq, Concurrent Atezolizumab)

Head and Neck Neoplasm · Head and Neck Neoplasm

#HeadandNeckNeoplasm#Antibody#Phase1#monoclonal-antibody#Medical
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

Dalpiciclib+cetuximab (Dalpiciclib+cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Active
AntibodyLimited DatastaleShanghai Ninth People's Hospita…Phase 2

Dalpicilib combined with cetuximab (Dalpicilib combined with cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Recruiting
CGTLimited DatastaleXinqiao Hospital of ChongqingPhase 2

EBV-specific TCR-T cell with anti-PD1 auto-secreted element (EBV-specific TCR-T cell with anti-PD1 auto-secreted element)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleBoehringer IngelheimPhase 1

Ezabenlimab (Ezabenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#Boehringer
Trials 1Status Recruiting
AntibodyLimited DatastaleGeneMedicine Co., Ltd.Phase 2

Part C (GM103 and Pembrolizumab, GM103 and Pembrolizumab (Part C))

Head and Neck Cancer; Malignant Melanoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#monoclonal-antibody#MalignantMelanoma+1
Trials 1Status Recruiting

2 / 4 pages

← PreviousNext →